TY - JOUR T1 - Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer JF - medRxiv DO - 10.1101/2020.03.31.20048637 SP - 2020.03.31.20048637 AU - Kartik Sehgal AU - Anushi Bulumulle AU - Heather Brody AU - Ritu R. Gill AU - Shravanti Macherla AU - Aleksandra Qilleri AU - Danielle C. McDonald AU - Cynthia R. Cherry AU - Meghan Shea AU - Mark S. Huberman AU - Paul A. VanderLaan AU - Glen J. Weiss AU - Paul R. Walker AU - Daniel B. Costa AU - Deepa Rangachari Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/31/2020.03.31.20048637.abstract N2 - Background Besides modeling/simulation-based analysis, no post-approval studies have evaluated optimal administration frequency of pembrolizumab in non-small cell lung cancer (NSCLC).Patients and Methods We performed a multicenter retrospective cohort study to evaluate association between survival outcomes and treatment extensions/delays of pembrolizumab-based regimens in advanced NSCLC patients. Those who had received at least four cycles in routine practice were divided into two groups: non-standard (Non-Std: ≥2 cycles at intervals >3weeks +3days) and standard (Std: all cycles every 3weeks or 1 cycle >3weeks +3days).Results Among 150 patients, 92 (61%) were eligible for the study (Non-Std:27, Std:65). Reasons for patients with extensions/delays in the Non-Std group included: immune-related adverse events (irAEs,33%), non-irAE-related medical issues (26%), and patient-physician preference (41%). Non-Std group was more likely to have higher PD-L1 tumor proportion score, higher number of treatment cycles and pembrolizumab monotherapy. Univariate and 6-month landmark analyses showed longer median overall survival (OS) and progression-free survival (PFS) in Non-Std group compared to the Std group. After multivariable adjustment for confounding factors, there was no significant difference in OS [HR 1.2 (95%C.I.: 0.3–4.8), p=0.824] or PFS [HR 2.6 (95%C.I.: 0.7–9.6), p=0.157] between the two groups.Conclusion Our study shows that a significant proportion of advanced NSCLC patients receive pembrolizumab-based regimens with extended intervals or delays in routine clinical practice and with similar outcomes to those receiving treatment at label-specified 3-week intervals. Given the durability of benefit seen and the potential for cost reduction and decreased infusion frequency in these patients, this requires validation in prospective trials.Competing Interest StatementDr. Rangachari reports nonfinancial support (institutional research support) from Bristol-Myers Squibb, Novocure, and Abbvie/Stemcentrx, all outside the submitted work. Dr. Costa reports personal fees (consulting fees and honoraria) and nonfinancial support (institutional research support) from Takeda/Millennium Pharmaceuticals, AstraZeneca, and Pfizer, as well as nonfinancial support (institutional research support) from Merck Sharp and Dohme Corporation, Merrimack Pharmaceuticals, Bristol-Myers Squibb, Clovis Oncology, Spectrum Pharmaceuticals and Tesaro, all outside the submitted work. Dr. Walker reports personal fees from ownership interest in Circulogene; all outside the submitted work. Dr. Weiss is an employee of Unum Therapeutics, outside of this work; reports personal fees from MiRanostics Consulting, Paradigm, Angiex, IBEX Medical Analytics, Spring Bank Pharmaceuticals, Pfizer, IDEA Pharma, GLG Council, Guidepoint Global, Ignyta, and Circulogene, all outside this work; has received travel reimbursement from Cambridge HealthTech Institute, GlaxoSmith Kline and Tesaro; has ownership interest in MiRanostics Consulting, Unum Therapeutics, and Circulogene, all outside the submitted work; and has a patent for methods and kits to predict prognostic and therapeutic outcome in small cell lung cancer issued, all outside the submitted work. Dr. VanderLaan has received personal fees (consulting fees and honoraria) from Gala Therapeutics, Flatiron Health, Caris Life Sciences, and Foundation Medicine; all outside the submitted work. Dr. Shea reports nonfinancial support (institutional research support) from Bristol-Meyers Squibb, Clovis Oncology, Pfizer, and Eli Lilly, all outside the submitted work. The remaining authors have no conflicts of interest to declare.Funding StatementThis work was supported in part by the National Institute of Health (NIH)/National Cancer Institute (NCI) [grant R37CA218707 awarded to Dr. Costa]. The funders/sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Health.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified data will be available upon reasonable request to the corresponding authors. ER -